Astellas Corrects a Part of Description of Press Release

Tokyo, April 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) corrected a part of a description of its press release titled “Astellas Announces Changes to Representative Director and Audit & Supervisory Board Member”, dated April 27, 2016. The detail of the correction is provided below.

(Error)

Tokyo, April 27, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that, at a meeting of its Board of Directors held today, it decided on the following changes to the Representative Director and Audit & Supervisory Board Member subject to the final approval by the Ordinary General Meeting of Shareholders scheduled on June 20, 2016.

(Correction)

Tokyo, April 27, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that, at a meeting of its Board of Directors held today, it decided on the following changes to the Representative Director and Audit & Supervisory Board Member. The changes to Audit & Supervisory Board Member are subject to the final approval by the Ordinary General Meeting of Shareholders scheduled on June 20, 2016.

###

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: 03-3244-3201 FAX: 03-5201-7473 http://www.astellas.com/en